Stephen Chang

US Patent:

6818439, Nov 16, 2004

Filed:

Dec 30, 1997

Appl. No.:

09/001039

Inventors:

Douglas J. Jolly - Leucadia CA
Stephen Chang - Poway CA
James G. Respess - Pacific Beach CA
Nicholas J. DePolo - Solano Beach CA
David Chi-Tang Hsu - San Diego CA
Carlos E. Ibanez - San Diego CA
Judith Greengard - San Diego CA
Lee Will - Carlsbad CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C12N 15867

US Classification:

4353201, 4352351, 435 691, 435 696, 530350, 530384, 536 231, 536 235

Abstract:

Methods are provided for obtaining measurable levels of a protein, nucleic acid molecule, or enzymatic product in a bodily fluid or cells of a human, comprising the step of administering to a human a recombinant retroviral preparation having a titer on HT1080 cells of greater than 10 cfu/ml, wherein the recombinant retroviral preparation is capable of directing the expression of a protein, nucleic acid molecule, or enzyme which generates an enzymatic product, such that measurable levels of the protein, nucleic acid molecule, or enzymatic product may be obtained in the bodily fluid or cells of the human.

US Patent:

7132100, Nov 7, 2006

Filed:

Jun 13, 2003

Appl. No.:

10/461904

Inventors:

Cynthia N. Oliver - N. Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/40
A61K 39/42
C07K 16/00

US Classification:

4241301, 4241331, 4241421, 4241471, 4241591, 5303871, 5303873, 5303881, 53038815, 5303883

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

7294336, Nov 13, 2007

Filed:

Feb 24, 2006

Appl. No.:

11/362267

Inventors:

Cynthia N. Oliver - N. Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471, 4241591

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

7425618, Sep 16, 2008

Filed:

Jun 13, 2003

Appl. No.:

10/461863

Inventors:

Cynthia N. Oliver - N. Potomac MD, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

Medimmune, Inc. - Gaithersburg MD

International Classification:

C12P 21/08

US Classification:

5303871, 5303881, 5303891, 4241591

Abstract:

The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.

US Patent:

7785592, Aug 31, 2010

Filed:

Oct 1, 2007

Appl. No.:

11/906543

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/40
A61K 39/42
C07K 16/00

US Classification:

4241331, 4241421, 4241471, 4241591, 5303871, 5303873, 5303881, 53038815, 5303883

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8007793, Aug 30, 2011

Filed:

Jun 16, 2010

Appl. No.:

12/817097

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471, 4241591

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8460663, Jun 11, 2013

Filed:

May 25, 2012

Appl. No.:

13/481640

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

A61K 39/395
A61K 39/42

US Classification:

4241301, 4241411, 4241471

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

US Patent:

8206951, Jun 26, 2012

Filed:

Jul 15, 2011

Appl. No.:

13/184455

Inventors:

Cynthia N. Oliver - North Potomac MD, US
Erica Shane - McLean VA, US
Benjamin S. Isaacs - Andover MA, US
Christian B. Allan - Brookeville MD, US
Stephen T. Chang - Frederick MD, US

Assignee:

MedImmune, LLC - Gaithersburg MD

International Classification:

C12N 5/07
C12N 5/16
C12P 21/04

US Classification:

435 7021, 435326, 435339

Abstract:

The present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.